Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: A case report and review of literature.
Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: A case report and review of literature.
复制标题
DOI：
10.1016/j.hemonc.2019.10.002
复制
发表时间：
2021-09-01
期刊：
影响因子：
--
通讯作者：
Adams, Carolyn Brooke
中科院分区：
文献类型：
--
作者：
Farhadfar, Nosha;Li, Ying;Adams, Carolyn Brooke
尽管T细胞急性淋巴细胞白血病（T-ALL）的一线治疗有所改善，但复发性T-ALL的结局仍然令人沮丧，只有不到7%的患者获得长期生存。因此，需要新的治疗策略来改善这种情况下的结局。细胞凋亡的抑制是抗癌药物耐药性的标志之一。因此，在过去的几年中，抗凋亡蛋白已成为一个有吸引力的目标，在几个血液恶性肿瘤的治疗干预。维奈托克（ABT-199）是一种新型的口服生物可利用的B细胞淋巴瘤2（BCL-2）小分子抑制剂，BCL-2是内在凋亡途径的关键调节剂。最近的临床前研究表明，抑制BCL-2可能是T-ALL患者的一种新的治疗策略。在此，我们报告了一例异基因干细胞移植后复发性T-ALL患者对维奈托克联合低甲基化剂的临床反应，并回顾了现有文献。
Despite improvements in first-line treatment of T-cell acute lymphoblastic leukemia (T-ALL), the outcome of relapsed T-ALL remains dismal with less than 7% achieving a long-term survival. Thus, there is an unmet need for new treatment strategies to improve outcomes in this setting. Suppression of apoptosis is one of the hallmarks of anticancer drug resistance. Hence, over the past few years, antiapoptotic proteins have become an attractive target for therapeutic intervention in several hematologic malignancies. Venetoclax (ABT-199) is a novel, orally bioavailable small-molecule inhibitor of B-cell lymphoma 2 (BCL-2), a key regulator of the intrinsic apoptotic pathway. Recent preclinical studies have suggested that inhibition of BCL-2 may be a novel therapeutic strategy for patients with T-ALL. Herein, we report a case of clinical response to venetoclax in combination with a hypomethylating agent in a patient with relapsed T-ALL after allogeneic stem cell transplant and review the existing literature.